SCHEMBL5759232

SCHEMBL5759232

CCCNC(=O)c1cn[nH]c1-c1cc2ccccc2[nH]1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITK Q08881 5/20 0.49
DRD2 P14416 2/20 0.49
DRD3 P35462 1/20 0.49
RIPK1 Q13546 1/20 0.43
HTR2C P28335 1/20 0.43
KDM4E B2RXH2 2/20 0.42
ALDH1A1 P00352 1/20 0.42
KDM5B Q9UGL1 1/20 0.41
INSR P06213 3/20 0.41
CCNE1 P24864 3/20 0.41
CDK2 P24941 3/20 0.41
GSK3B P49841 3/20 0.41
BRD4 O60885 1/20 0.41
HSD17B10 Q99714 1/20 0.41
HDAC3 O15379 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC2 Q92769 1/20 0.41
NCOR2 Q9Y618 1/20 0.41
AKR1C3 P42330 1/20 0.40
ALOX15 P16050 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5756245 0.93 DRD2 (0.59) ITKDRD2DRD3HTR2CKDM4E
SCHEMBL5756565 0.91 ITK (0.46) ITKDRD2DRD3RIPK1KDM4E
SCHEMBL5753974 0.86 HTR2C (0.52) ITKDRD2DRD3HTR2CKDM4E
SCHEMBL5753389 0.85 ITK (0.44) ITKINSRCCNE1CDK2GSK3B
SCHEMBL5756905 0.84 BRD4 (0.45) ITKKDM4EALDH1A1INSRCCNE1
SCHEMBL5755119 0.84 HSP90AA1 (0.57) ITKKDM4EINSRCCNE1CDK2
SCHEMBL5755157 0.81 DCAF1 (0.45) ITKRIPK1CCNE1CDK2GSK3B
SCHEMBL5752698 0.80 HSP90AA1 (0.55) ITKHSP90AA1HSP90AB1
SCHEMBL5755243 0.80 ITK (0.46) ITKKDM4EALDH1A1BRD4HSD17B10
SCHEMBL6489610 0.80 KDM4E (0.48) ITKKDM4EALDH1A1CCNE1CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1648884-A2 PYRAZOLYL-INDOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM Pharmacia Italia S.p.A. (IT) 2006-04-26 EP disclosed
US-20050032869-A1 Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them PHARMACIA ITALIA S.P.A. (IT) 2005-02-10 US disclosed
WO-2005005414-A2 PYRAZOLYL-INDOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM PHARMACIA ITALIA S.P.A. (IT) 2005-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050032869-A1 Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them MAP3K9, MAP3K20, MAP3K19 ITK 392/4885DRD2 3783/4885DRD3 4095/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.